January 25, 2021 – Philadelphia, PA – We are pleased to announce that Dr. Weiwei Hu will be joining WuXi Advanced Therapies Unit (WuXi ATU), as Vice President, China Process Development and Tech Transfer Head.

Dr. Weiwei Hu brings extensive industry experience in biopharmaceutical and cell therapy technical development.  He joins us most recently from the Cell Therapy Development and Operations (CTDO) division of Bristol-Myers Squibb, where he was Director of Cell Process Development leading late-stage process change and implementation as well as supporting global regulatory filings including BLA and MAA. He also built a new team focusing on cell culture process innovations in the cell therapy area.

Before that, he worked at Celgene as one of the founding members to build Celgene’s internal biologics process development capability from the ground up and has contributed significantly to the progress of all their internal biologics pipeline projects, including complex recombinant proteins and bispecific antibodies as well as cell-free protein synthesis, from pre-IND to BLA filing. His accomplishments also consist of successful collaborations with six different CMOs on tech transfer and manufacturing campaign support.

Prior to Celgene, Dr. Weiwei Hu has worked on biologics process development at Biogen for nine years, where he held positions of increasing responsibility. His experience and expertise include cell culture media and process development, tech transfer and scale-up, pilot plant operation, manufacturing support, and critical raw material control. In his last role, he managed Biogen’s pilot scale upstream teams and oversaw all the cell culture scale-up activities in Biogen’s global manufacturing networks. With demonstrated ability and track record to drive innovation and implementation, he has made significant contributions to the development of Biogen’s novel, high-performance platform technologies including the development of proprietary chemically defined media for high-titer fed-batch processes, biosimilar product quality control, the characterization of 15,000L bioreactor, and the development of a customized perfusion system for large-scale inoculation bioreactor.

Dr. Weiwei Hu earned his Ph.D. in Chemical Engineering from The Ohio State University, as well as a M.S. and B.S. in Biochemical Engineering from East China University of Science and Technology.

We are excited to welcome Dr. Hu to WuXi Advanced Therapies!

 

About WuXi Advanced Therapies (ATU)

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the development, testing, manufacturing, and commercialization of cell, gene, and other advanced biopharmaceuticals. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit www.advancedtherapies.com

 

Media Contact:
Min Park
Global Head of Marketing
WuXi Advanced Therapies
atu.info@wuxiapptec.com